OncoSTING is developing recombinant STING agonist
immunotherapies including OS-151 and others.
These live BCG-based immunotherapies are engineered to deliver sustained release
of potent STING agonists and to retain the known efficacy of traditional
BCG against bladder cancer. Propriety technology also reduces adverse
events associated with traditional BCG.
immunotherapies including OS-151 and others.
These live BCG-based immunotherapies are engineered to deliver sustained release
of potent STING agonists and to retain the known efficacy of traditional
BCG against bladder cancer. Propriety technology also reduces adverse
events associated with traditional BCG.
OS-151
STING agonists, small molecules that trigger proinflammatory innate immune responses against tumors, show promise to revolutionize cancer immunotherapy. OS-151 is a second-generation BCG immunotherapy for bladder cancer which produces high levels of a potent STING agonist and at the same time retains the known efficacy of traditional BCG. OncoSTING’s preclinical research and development has revealed that OS-151 is more effective than traditional BCG in multiple models of bladder cancer. Additionally, OS-151 has an improved safety profile compared to traditional BCG in preclinical studies.
OS-151 is being developed for distinct forms of cancer:
Bladder Cancer
Bladder cancer afflicts ~80,000 US individuals annually. Two-thirds of cases are non-muscle invasive bladder cancer (NMIBC). NMIBC patients
receive intravesical traditional BCG immunotherapy but 30% will have BCG unresponsive disease.
Bladder cancer afflicts ~80,000 US individuals annually. Two-thirds of cases are non-muscle invasive bladder cancer (NMIBC). NMIBC patients
receive intravesical traditional BCG immunotherapy but 30% will have BCG unresponsive disease.
Solid Tumors
Tumors such as malignant melanoma have
been treated successfully with STING
agonists and also traditional BCG. OS-151 is being developed as an intratumoral immunotherapy for certain solid tumors
Tumors such as malignant melanoma have
been treated successfully with STING
agonists and also traditional BCG. OS-151 is being developed as an intratumoral immunotherapy for certain solid tumors